Comparison of two type of steroidal eyedrops in treatment of uveitis

Comparison of the efficacy and extend of ocular surface toxicity between a preservative- free methylprednisolone topical preparation and preserved prednisolone eye drop in the treatment of acute anterior uveitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012101511125N1

Enrollment

Registered

2013-03-09

Start date

2013-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute anterior uveitis. Acute and subacute iridocyclitis

Interventions

Intervention 1: In case group: self- instillation of nonpreserved methylprednisolone sodium succinate 1 % every hour one eye drop during daytime for the first week and then upon clinical response. I

Treatment - Drugs

In case group: self- instillation of nonpreserved methylprednisolone sodium succinate 1 % every hour one eye drop during daytime for the first week and then upon clinical response

In control group: self- instillation of preserved prednisolone acetate 1% (Pred Forte 1%, Allergan, Inc) every hour one eye drop during daytime for the first week then upon clinical response

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: Eligibility criteria were: 1- age 16 years or older; 2- attack duration less than one week period; 3- no high intraocular pressure at presentation; 4-negative clues for infectious (e.g. corneal scars, iris atrophy) or granulomatous inflammation (e.g. granulomatous keratic precipitate or iris nodule). The following exclusion criteria would be used: 1-eyes with hypopyon or florid fibrin formation; 2-prior unsuccessful topical treatment; 3- known cases of Behcet disease; 4-any slit-lamp evidence of significant blepharitis or meibomian gland dysfunction; 5-recent use of contact lenses.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Anterior chamber inflammation. Timepoint: 1 week and 2 week after treatment. Method of measurement: Anterior chamber flare would be assessed using the laser flare photometer .anterior chamber cell would be assessed using slit lamp by standard grading system (1-4, SUN).	—

Secondary

Measure	Time frame
Corneal toxicity. Timepoint: 1 week and 2 week after treatment. Method of measurement: Schirmer I test, tear break-up time, and corneal fluorescein staining scores.;Subjective discomfort. Timepoint: 1 week and 2 week after treatment. Method of measurement: Questionary.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Hedayatfar

NOOR EYE HOSPITAL

ahedayatfar@norc.ac.ir+98 21 82400

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026